PD-1单克隆抗体联合血管内皮抑素在Lewis肺癌小鼠的抗肿瘤效应

doi:10.6040/j.issn.1671-7554.0.2018.251

摘要/Abstract

摘要： 目的探讨程序性死亡受体-1(PD-1)单克隆抗体联合血管内皮抑素对Lewis肺癌小鼠的抗肿瘤效应。方法构建Lewis肺癌C57BL/6小鼠移植瘤模型,随机分为4个组:PBS对照组(A组)、PD-1单克隆抗体组(B组)、血管内皮抑素组(C组)、PD-1单克隆抗体联合血管内皮抑素组(D组)。测量小鼠肺内肿瘤体积,ELISA检测小鼠血浆中INFγ的含量,免疫组织化学染色检测肿瘤组织的CD31和VEGF。结果与A组相比,B组、D组肿瘤生长受到明显抑制(P均<0.001),C组肿瘤虽有缩小但差异无统计学意义(P=0.084);与A组相比,B、C、D组血浆中INFγ的浓度明显升高(P均<0.001),D组升高最为明显;与A组相比,D组小鼠肿瘤组织中VEGF的阳性表达最低(P<0.001);MVD计数D组降低,与A组相比(P<0.001),D组与B组相比(P=0.019),D组与C组相比(P<0.001)。结论 PD-1单克隆抗体联合血管内皮抑素治疗明显减缓肿瘤生长速度,有效改善肿瘤微环境,有明显协同抗肿瘤作用。

关键词: 肺肿瘤, 程序性死亡受体-1, 血管内皮抑素, 肿瘤微环境

Abstract: Objective To explore the antitumor effect of anti-PD-1 combined with angioendostatin on lung cancer in Lewis mice. Methods Lewis lung cancer C57BL/6 mice models were constructed and randomly divided into 4 groups: group A(PBS control), group B(anti-PD-1), group C(endostatin)and group D(anti-PD-1 combined with endostatin). The tumor volume was measured. The content of INFγ in the plasma was detected with ELISA, and the CD31 and VEGF contents were determined with immunohistochemistry. Results Compared with group A, group B and D had significantly inhibited tumor growth(P<0.001); group C had reduced tumor size but there was no statistical difference(P=0.084). Compared with group A, groups D, C and B had significantly elevated INFγ concentration(P<0.001), and group D showed the most obvious increase. Compared with group A, group D had significantly lower positive expression of VEGF(P<0.001). MVD count decreased significantly in group D compared with that in group A(P<0.001), group D compared with group B(P=0.019), and group D compared with group C(P<0.001). Conclusion Anti-PD-1 combined with endostatin can significantly slow down the tumor growth, effectively improve the tumor microenvironment, and play a synergistic antitumor effect.

Key words: Lung cancer, Programmed cell death-1, Endostatin, Tumor microenvironment

中图分类号:

R734.2

姜运峰,董晓鹏,赵小刚. PD-1单克隆抗体联合血管内皮抑素在Lewis肺癌小鼠的抗肿瘤效应[J]. 山东大学学报 (医学版), 2018, 56(9): 11-16.

JIANG Yunfeng, DONG Xiaopeng, ZHAO Xiaogang. Combinatorial anti-PD-1 and endostatin therapeutic efficacy in Lewis lung cancer mice[J]. Journal of Shandong University (Health Sciences), 2018, 56(9): 11-16.

参考文献

[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] Zeng H, Zheng R, Guo Y, et al. Cancer survival in China, 2003-2005: a population-based study[J]. Int J Cancer, 2015, 136(8): 1921-1930.
[3] Zheng YW, Li RM, Zhang XW, et al. Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome[J]. Cancer Invest, 2013, 31(3): 197-205.
[4] Folkman J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971, 285(21): 1182-1186.
[5] O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth[J]. Cell, 1997, 88(2): 277-285.
[6] Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy[J]. Angiogenesis, 2017, 20(2): 185-204.
[7] Liang J, Liu X, Xie Q, et al. Endostatin enhances antitumor effect of tumor antigen-pulsed dendritic cell therapy in mouse xenograft model of lung carcinoma[J]. Chin J Cancer Res, 2016, 28(4): 452-460.
[8] Folkman J, Watson K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia[J]. Nature, 1989, 339(6219): 58-61.
[9] Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action[J]. Exp Cell Res, 2006, 312(5): 594-607.
[10] Zhao X, Su Y, You J, et al. Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA(N2)non-small cell lung cancer without increasing adverse effects[J]. Oncotarget, 2016, 7(38): 62619-62626.
[11] Gampenrieder SP, Westphal T, Greil R. Antiangiogenic therapy in breast cancer[J]. Memo, 2017, 10(4): 194-201.
[12] Yao S, Zhu Y, Chen L. Advances in targeting cell surface signaling molecules for immune modulation[J]. Nat Rev Drug Discov, 2013, 12(2): 130-146.
[13] Siwiec A, Majdan M. The role of the PD-1 protein in pathogenesis of autoimmune diseases, with particular consideration of rheumatoid arthritis and systemic lupus erythematosus[J]. Postepy Hig Med Dosw(Online), 2015, 69: 534-542. doi:10.5604/17322693.1150784.
[14] Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1(MDX-1106)in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates[J]. J Clin Oncol, 2010, 28(19): 3167-3175.
[15] Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26): 2443-2454.
[16] Qian N, Gao L, Dong L, et al. Construction, expression, purification, and characterization of a dual-targeting PD-1/VEGF-A fusion protein(P-V)[J]. Protein Expr Purif, 2015, 109: 1-6. doi:10.1016/j.pep.2015.01.004.
[17] Schmittnaegel M, Rigamonti N, Kadioglu E, et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade[J]. Sci Transl Med, 2017, 12, 9(385). doi:10.1126/scitranslmed.aak9670.
[18] Yasuda S, Sho M, Yamato I, et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2(VEGFR2)induces synergistic anti-tumour effect in vivo[J]. Clin Exp Immunol, 2013, 172(3): 500-506.
[19] Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy[J]. Science, 2005,307(5706): 58-62.
[20] Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis[J]. Nat Med, 2013, 19(11): 1423-1437.
[21] Gunaje JJ, Bahrami AJ, Schwartz SM, et al. PDGF-dependent regulation of G protein signaling-5 expression and vascular smooth muscle cell functionality[J]. Am J Physiol Cell Physiol, 2011, 301(2): C478-489.
[22] 何朗, 孙永红, 蒋莉, 等. rh-Endostatin与肿瘤血管正常化时相的关系初探[J]. 中华肿瘤防治杂志, 2016, 23(19): 1291-1296. HE Lang, SUN Yonghong, JIANG Li, et al. Preliminary research of the relationship between rh-Endostatin and micro-vascular normalization course[J]. Chin J Cancer Prevention Treatment, 2016, 23(19): 1291-1296.
[23] Peng Q, Li M, Wang Z, et al. Polarization of tumor-associated macrophage is associated with tumor vascular normalization by endostatin[J]. Thorac Cancer, 2013, 4(3): 295-305.
[24] Ishikawa H, Nakao K, Matsumoto K, et al. Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene[J]. Hepatology, 2003, 37(3): 696-704.

相关文章 15

[1]	庞兆飞,柳勇,赵小刚,闫涛,陈效伟,杜贾军. 基于公共数据库构建肺腺癌肿瘤干性评分模型预测免疫治疗疗效[J]. 山东大学学报 (医学版), 2021, 59(11): 19-28.
[2]	石树远,关志宇,孙大强. 重组人血管内皮抑素增强EGFR-TKIs对肺癌的抗瘤作用[J]. 山东大学学报 (医学版), 2018, 56(9): 6-10.
[3]	黄竹青,吴雪韦,任冬梅. 槲寄生中酚类化学成分的分离鉴定及其对A549细胞的增殖抑制活性[J]. 山东大学学报（医学版）, 2017, 55(8): 35-41.
[4]	曾奕明,林燕萍. 放射性¹²⁵I粒子植入局部治疗支气管肺癌[J]. 山东大学学报（医学版）, 2017, 55(4): 1-6.
[5]	霍彬,王磊,王海涛,霍小东,曹强,王丽丽,臧立,王金焕,郑广钧, 柴树德. 模板联合肋骨钻孔技术辅助放射性粒子植入治疗肺癌的可行性[J]. 山东大学学报（医学版）, 2017, 55(2): 26-31.
[6]	韩明勇,霍彬,张颖,林琦,戴建建,徐瑞彩,杨琦,耿宝成,郑广钧,王海涛,霍小东,陈宝明(柴树德,王俊杰审阅). CT联合模板引导放射性粒子植入治疗肺癌技术流程[J]. 山东大学学报（医学版）, 2017, 55(2): 14-20.
[7]	路真真,颜磊,张辉,张晓晖,赵兴波. 肿瘤微环境中TGF β-1对子宫内膜间质细胞活化的影响[J]. 山东大学学报（医学版）, 2016, 54(9): 37-40.
[8]	杨晖,董蓉,薛慧,胡祖权,曾柱. 肝癌细胞对人成熟树突状细胞影响的基因芯片分析[J]. 山东大学学报（医学版）, 2016, 54(1): 1-6.
[9]	李星宇, 梁婧, 李岩. 血管内皮抑素协同肿瘤特异性DC-T细胞的抗肿瘤效应[J]. 山东大学学报（医学版）, 2015, 53(7): 19-23.
[10]	陈少平, 王旬果, 郭燕春, 刘瑞宝, 王芳. 重组人血管内皮抑素在晚期消化道肿瘤化疗中的应用[J]. 山东大学学报（医学版）, 2014, 52(S1): 122-124.
[11]	贾颖，祖珊珊，郏雁飞，肖东杰，汪运山，马晓丽. CHRNA5基因表达下调对肺癌细胞VEGF表达的影响[J]. 山东大学学报（医学版）, 2014, 52(2): 12-15.
[12]	张淼慈, 李萍, 哈敏文. 重组人血管内皮抑素联合吉西他滨治疗铂类耐药复发卵巢癌的临床观察[J]. 山东大学学报（医学版）, 2014, 52(11): 55-59.
[13]	孙越,刘香岚,王群,郭春,石永玉,张利宁. 人TIPE家族新成员TIPE3特异性抗体的鉴定及应用[J]. 山东大学学报（医学版）, 2014, 52(1): 5-9.
[14]	祖珊珊1，马晓丽1,2，郏雁飞1,2，赵云3，贾颖1，肖东杰1,2，汪运山1,2. α5-烟碱型乙酰胆碱受体表达下调对肺癌细胞HIF-1α表达的影响[J]. 山东大学学报(医学版), 2013, 51(9): 8-12.
[15]	张林1，张振江2，孟龙1，马伟1，杜贾军1. 恶性局灶性磨玻璃样肺结节的外科治疗[J]. 山东大学学报(医学版), 2013, 51(9): 84-87.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed